A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Latest Information Update: 13 Sep 2023
At a glance
- Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Alkermes plc
- 11 Sep 2023 According to a Alkermes media release, results of meta-analysis using individual subject-level data from this trial presented at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville.
- 08 Mar 2019 Results published in the American Journal of Psychiatry
- 28 Mar 2016 Data will be presented at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference 2016, according to an Alkermes plc media release.